Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Санкт-Петербургский государственный университет Городская психиатрическая больница №1 им. П.П.Кащенко, Санкт-Петербург
Список исп. литературыСкрыть список 1. Андреев Б.В. Фармакологические свойства и особенности действия современных антидепрессантов (обзор). Обозрение психиатрии и мед. психологии. 2000; 1: 23–7. 2. Андреев Б.В. Атипичные антипсихотические средства нового поколения: итоги и перспективы. Обозрение психиатрии и мед. психологии. 2005; 2: 4–8. 3. Abbas AI, Hedlund PB, Huang XP et al. Amisulpride is a potent 5HT7-antagonist: relevance for antidepressant actions in vivo. Psychopharmacol 2009; 205 (1): 119–28. 4. Abi-Dargham A, Moore H. Prefrontal DA transmission at D1-receptors and the pathology of schizophrenia. Neuroscientist 2003; 9: 404–16. 5. Arnt J, Skarsfeld T. Do novel antipsychotics have similar pharmacological characteristics? A reviev of the evidence. Neuropsychopharmacol 1998; 18: 63–101. 6. Arnt J, Bang-Andersen B, Grayson B et al. Lu AE58054, a 5HT6-antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol 2010; 13: 1021–33. 7. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacol 2001; 25 (1): 1–27. 8. Burghardt NS, Bush DE, McEwen BS, Le Doux JE. Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5HT2C-receptor antagonist. Biol Psychiat 2007; 62 (10): 1111–8. 9. Burnet PW, Eastwood SL, Harrison PJ. [3H]WAY-100635 for 5HT1A-receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 1997; 30 (6): 565–74. 10. Chanbari R, El Mansari M, Shahid M, Blier P. Electrophisiological characterization of the effects of asenapine at 5HT1A-, 5HT2A-, a2-adrenergic and D2-receptors in the rat brain. Europ Neuropsychopharmacol 2009; 19 (3): 177–87. 11. Costall B, Domeney AM, Kelly ME et al. Actions of ORG 5222 as a novel psychotropic agent. Pharmacol, Biochem and Behav 1990; 35 (3): 607–15. 12. Da Silva Costa V, Duchatelle P, Boulouard M, Dauphin F. Selective 5HT6-receptor blockade improves spatial recognition memory and reverses age-related deficits in spatial recognition memory in the mouse. Neuropsychopharmacol 2009; 34 (2): 488–500. 13. De Boer T, Tonnaer JA, De Vos CJ, Van Delft AM. Neurochemical studies with the potential antipsychotic compound trans-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine maleate. Arzneimittelforschung 1990; 40 (5): 550–4. 14. De Deurwaerdere P, Navailles S, Berg KA et al. Constitutive activity of the serotonin 2C-receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. Neuroscience 2004; 24: 3235–41. 15. Elsworth JD, Groman SM, Jentsch JD et al. Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration. Neuropharmacol 2012; 62 (3): 1442–52. 16. Food and Drug Administration. FDA labelling information. FDA website 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022117s000lbl.pdf 17. Fox SH, Chuang R, Brotchie JM. Parkinson\'s disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog Brain Res 2008; 172: 479–94. 18. Francis PT, Pangalos MN, Pearson RC et al. 5-hydroxytryptamine1A but not 5-hydroxytryptamine2-receptors are enriched on neocortical pyramidal neurons destroyed by intrastriatal volkensin. J Pharmacol and Experim Therapeut 1992; 261 (3): 1273–81. 19. Franberg O, Wiker C, Marcus MM et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacol 2008; 196: 417–29. 20. Franberg O, Marcus MM, Ivanov V et al. Asenapine elevates cortical dopamine, noradrenalin and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacol 2009; 204 (2): 251–64. 21. Franberg O, Marcus MM, Svensson TN. Involvement of 5HT2A-receptor and a2-adrenoreceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow. Synapse 2012; 66 (7): 650–60. 22. Goldman-Rakic PS, Castner SA, Svensson TH et al. Targeting the dopamine D1-receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacol 2004; 174: 3–16. 23. Greenwood BN, Strong PV, Brooks L, Fleshner M. Anxiety-like behaviors produced by acute fluoxetine administration in male Fischer 344 rats are prevented by prior exercise. Psychopharmacol Berl 2008; 199 (2): 209–22. 24. Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiat 1997; 42 (7): 529–45. 25. Guscott M, Bristow LJ, Hadingham K et al. Genetic knockout and pharmacological blockade studies of the 5HT7-receptor suggest therapeutic potential in depression. Neuropharmacol 2005; 48 (4): 492–502. 26. Hajós M. Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends Pharmacol Sci 2006; 27: 391–8. 27. Heal DJ, Smith SL, Fisas A et al. Selective 5HT6-receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol and Therapeut 2008; 117 (2): 207–31. 28. Homayoun H, Moghaddam B. NMDA-receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007; 27: 11 496–500. 29. Huang M, Li Z, Dai J et al. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacol 2008; 33: 2934–45. 30. Johnson CN, Ahmed M, Miller ND. 5HT6-receptor antagonists: prospects for the treatment of cognitive disorders including dementia. Current Opin Drug Discov Development 2008; 11 (5): 642–54. 31. Jardemark K, Marcus MM, Shahid M, Svensson TH. Effects of asenapine on prefrontal N-methyl-D-aspartate receptor-mediated transmission: Involvement of dopamine D1-receptors. Synapse 2010; 64: 870–4. 32. Kane JM, Mackle M, Snow-Adami L et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiat 2011; 72 (3): 349–55. 33. Kuoppamaki M, Seppala T, Syvalahti E, Hietala J. Chronic clozapine treatment decreases 5-hydroxytryptamine 1C-receptor density in the rat choroid plexus: comparison with haloperidol. J Pharmacol Experim Therap 1993; 264 (3): 1262–7. 34. Marston HM, Young JW, Martin FD et al. Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacol 2009; 206: 699–714. 35. Marston HM, Martin F, Papp M et al. Attenuation of chronic mild stress-induced «anhedonia» by asenapine is not associated with a «hedonic» profile in intracranial self-stimulation. J Psychopharmacol 2011; 25 (10): 1388–98. 36. McIntyre RS, Cohen M, Zhao J et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Dis 2010; 122 (l–2): 27–38. 37. Meltzer HY. Suicide and schizophrenia: clozapine and the Inter SePT Study. J Clin Psychiat 1999; 60 (Suppl. 12): 47–50. 38. Meltzer HY, Massey DW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Current Option Pharmacol 2011; 11: 59–67. 39. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin 5HT1A-receptors. J Pharmacol Experim Therap 2000; 295 (3): 853–61. 40. Millan MJ. Serotonin 5HT2C-receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Thérapie 2005; 60: 441–60. 41. Mnie-Filali O, Faure C, Lambas-Senas L et al. Pharmacological blockade of 5HT7-receptors as a putative fast acting antidepressant activity. Neuropsychopharmacol 2011; 36: 1275–88. 42. Ninan PT, Muntasser P. Buspirone and geropirone. In: A.Schatzberg, C.Nemeroff (eds). Textbook of psychopharmacology. Arlington VA: American Psychiatric Press 2004; p. 391–404. 43. Pitsikas N, Zisopoulou S, Pappas I, Sakellaridis N. The selective 5HT6-receptor antagonist Ro 04-6790 attenuates psychotomimetic effects of the NMDA-receptor antagonist MK-801. Behav Brain Res 2010; 188: 304–9. 44. Prinssen EP, Koek W, Kleven MS. The effects of antipsychotics with 5HT2C-receptor affinity in behavioral assays selective for 5HT2C-receptor antagonist properties of compounds. Eur J Pharmacol 2000; 388: 57–67. 45. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiat 2007; 68: 1492–500. 46. Psychotropics (the Lundbeck Institute website): www.luinst.org 47. Rauser L, Savage JE, Meltzer HY, Roth BL. Inverse actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine 2C-receptor. J Pharm Exp Ther 2001; 299: 83–9. 48. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life sciences 2000; 68 (1): 29–39. 49. Roth BL, Sheffler D, Potkin SJ. Atypical antiosychotic drug actions: unitary or multiple mechanisms for «atypicality». Clin Neurosci Research 2003; 3: 107–17. 50. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009; 23: 65–73. 51. Snigdha S, Idris N, Grayson B et al. Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1-receptor mechanism. Psychopharmacol 2011; 214 (4): 843–53. 52. Schotte A, Janssen PF, Gommeren W et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacol 1996; 124 (1–2): 57–3. 53. Sumiyoshi T, Matsui M, Yamashita I et al. Effect of adjunctive treatment with serotonin 1A-agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol 2000; 20 (3): 386–8. 54. Sumiyoshi T, Matsui M, Yamashita I et al. The effect of tandospirone, a serotonin 1A-agonist, on memory function in schizophrenia. Biol Psychiat 2001; 49 (10): 861–8. 55. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A-, 2A- and 2C-receptors in rat forebrain regions. Psychopharmacol 2002; 161 (3): 263–70. 56. Tarazi FI, Morgan-Gates T, Wong EH et al. Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol 2010; 24 (3): 341–8. 57. Tecott LH, Sun LM, Akana SF et al. Eating disorder and epilepsy in mice lacking 5HT2С-serotonin receptors. Nature 1995; 374 (6522): 542–6. 58. Thomas DR, Hagan JJ. 5HT7-receptors. Current Drug Targets CNS Neurol Dis 2004; 3 (1): 81–90. 59. Zupancic M, Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006; 20 (12): 981–92.